Compare CNF & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CNF | NEUP |
|---|---|---|
| Founded | 1999 | 1996 |
| Country | China | United States |
| Employees | N/A | 8 |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.2M | 23.8M |
| IPO Year | 2018 | N/A |
| Metric | CNF | NEUP |
|---|---|---|
| Price | $2.85 | $4.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 2.8K | ★ 44.8K |
| Earning Date | 05-05-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $252.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $3.65 |
| 52 Week High | $24.00 | $21.31 |
| Indicator | CNF | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 35.75 | 62.31 |
| Support Level | $2.72 | $3.85 |
| Resistance Level | $5.13 | $5.18 |
| Average True Range (ATR) | 0.19 | 0.22 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 25.87 | 87.21 |
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.